Cellectis
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Cellectis and buy or sell other stocks, ETFs, and their options commission-free!About CLLS
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J.
CEOAndré Choulika
CEOAndré Choulika
Employees229
Employees229
HeadquartersParis, Ile-de-France
HeadquartersParis, Ile-de-France
Founded2000
Founded2000
Employees229
Employees229
CLLS Key Statistics
Market cap235.57M
Market cap235.57M
Price-Earnings ratio-4.98
Price-Earnings ratio-4.98
Dividend yield—
Dividend yield—
Average volume12.31K
Average volume12.31K
High today$3.41
High today$3.41
Low today$3.21
Low today$3.21
Open price$3.41
Open price$3.41
Volume4.71K
Volume4.71K
52 Week high$5.48
52 Week high$5.48
52 Week low$2.35
52 Week low$2.35
CLLS News
TipRanks 4d
Cellectis Updates Share Capital and Voting Rights as of August 31, 2026Cellectis SA ( (FR:ALCLS) ) just unveiled an announcement. Cellectis SA reported that as of August 31, 2026, its share capital consisted of 100,718,974 shares,...
TipRanks 6d
Cellectis Plans Heavy Investor Conference Schedule for Fall 2026Cellectis SA ( (CLLS) ) just unveiled an update. On September 1, 2026, Cellectis announced that it would engage actively with the investment community through...
Analyst ratings
86%
of 7 ratingsBuy
85.7%
Hold
14.3%
Sell
0%
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.